Fo­cused on block­buster in­di­ca­tions, Sage touts ev­i­dence that 217 could work on in­som­nia

Af­ter whip­ping up some gid­dy block­buster ex­pec­ta­tions for their oral drug SAGE-217 in de­pres­sion, Sage Ther­a­peu­tics is back this morn­ing with an ear­ly snap­shot on new da­ta for an­oth­er mass mar­ket — in­som­nia.

Tout­ing the drug’s abil­i­ty to “re­bal­ance fun­da­men­tal brain cir­cuit­ry,” re­searchers spot­light­ed a Phase I/II hit for sev­er­al mea­sures on im­prov­ing the amount of sleep in­som­ni­acs can achieve.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER